Press Release Archive
Press Releases
January 2023
01.06.2023 Corporate Partnerships Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases 01.03.2023 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
December 2022
12.29.2022 Medicines Research Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate 12.28.2022 Vaccines Vaccines U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents 12.21.2022 Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis 12.20.2022 Financial Finance Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts 12.10.2022 Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial 12.09.2022 Financial Finance Pfizer Declares First-Quarter 2023 Dividend 12.08.2022 Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years 12.07.2022 Vaccines Vaccines U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults 12.06.2022 Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease 12.05.2022 Vaccines Covid-19 Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.